4.7 Review

Toxicological overview of impurities in pharmaceutical products

Journal

ADVANCED DRUG DELIVERY REVIEWS
Volume 59, Issue 1, Pages 38-42

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2006.10.007

Keywords

toxicology; pharmaceutical impurities; European medicines agency (EMEA); genotoxic impurities

Ask authors/readers for more resources

While the use of pharmaceuticals is always a balance of risks and benefits, the same is not true for impurities in pharmaceuticals; impurities convey only risk. A number of international guidelines and regional guidances instruct drug developers and regulatory agencies on how to evaluate and control impurities in drug substances and drug products. While impurities should always be reduced to the lowest levels that are reasonably practical, it is acknowledged that impurities cannot be reduced to zero and specifications for impurities need to be established. This chapter discusses practical and theoretical methods for qualification of different classes of impurities. (c) 2006 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available